a.) Amendments to the Claims

1. (Cancelled)

2. (Cancelled)

3. (Amended) A method of ~~preparing a drug encapsulated in liposomes~~ inhibiting the leakage of an encapsulated drug in the presence of a biological component, which comprises the steps of: ~~selecting a drug and encapsulating said drug satisfying at least two requirements selected from the group consisting of: using at least two lipid bilayers of the liposomes, controlling the~~

selecting a lipid from the group consisting of phospholipid, glyceroglycolipid and sphingoglylcolipid with a phase transition temperature higher than *in vivo* temperature; and

encapsulating said drug within liposomes consisting of said lipid, wherein said liposomes have an average particle size of ~~the liposomes to~~ 120 to 500 nm ~~or more, and using lipid having a phase transition temperature higher than *in vivo* temperature as lipid constituting the liposomes~~.

4. (Amended) The method of inhibiting the leakage according to claim ~~2 or~~ 3, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, and polyethylene glycol-modified

phospholipid~~, and cholesterol~~.

5. (Amended) The method of inhibiting the leakage according to claim ~~2 or~~ 3, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, and polyethylene glycol-modified phospholipid~~, and cholesterol~~.

6. (Cancelled)

7. (Cancelled)

8. (Amended) The method of inhibiting the leakage according to any one of claims ~~1 to 3 or 6~~ 3 to 5, wherein the biological component is a blood component.

9. (Amended) The method of inhibiting the leakage according to ~~claim 8~~ any one of claims 3 to 5, wherein the drug encapsulated is an indolocarbazole derivative.

10. (Amended) The method of inhibiting the leakage according to ~~claim 8~~ any one of claims 3 to 5, wherein the drug encapsulated is an antitumor agent.

11. (Amended) The method of inhibiting the leakage according to ~~claim 8~~ any one of claims 3 to 5, wherein the drug encapsulated is an antibiotic.

12. (Amended) The method of inhibiting the leakage according to ~~claim 8~~ any one of claims 3 to 5, wherein the drug encapsulated is a pharmaceutically active substance.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Currently Amended) A ~~liposome preparation~~ pharmaceutical composition comprising a ~~an encapsulated~~ drug encapsulated in a liposome with~~, wherein said liposome satisfies at least two requirements selected from the group consisting of: the number of lipid bilayers of the liposomes is at least two, the liposomes have~~ an average particle size of 120 to 500 nm ~~or more~~, and consisting of lipid ~~constituting the liposomes has~~ having a phase transition temperature higher than *in vivo* temperature selected from the group consisting of phospholipid, glyceroglycolipid and sphingoglylcolipid.

17. (Cancelled)

18. (Cancelled)

19. (Amended) The liposome preparation according to ~~any one of claims 14 to 16~~ claim 16, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine~~,~~ and polyethylene glycol-modified phospholipid~~, and cholesterol~~.

20. (Amended) The liposome preparation according to ~~any one of~~ claims 16 ~~14 to 16~~, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine~~,~~ and polyethylene glycol-modified phospholipid~~, and cholesterol~~.

21. (Cancelled)

22. (Amended) The liposome preparation according to any one of claims 16, 19 and 20 ~~21~~, wherein the drug encapsulated is an indolocarbazole derivative.

23. (Amended) The liposome preparation according to any one of claims 16, 19 and 20 ~~21~~, wherein the drug encapsulated is an antitumor agent.

24. (Amended) The liposome preparation according to any one of claims 16, 19 and 20 ~~21~~, wherein the drug encapsulated is an antibiotic.

25. (Amended) The liposome preparation according to any one of

claims 16, 19 and 20 ~~21~~, wherein the drug encapsulated is a pharmaceutically active substance.

26. (New) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is an indolocarbazole derivative.

27. (New) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is an antitumor agent.

28. (New) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is an antibiotic.

29. (New) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is a pharmaceutically active substance.

30. (New) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein said liposome comprises at least two bilayers of said lipid.

31. (New) The method of inhibiting the leakage according to claim 26, wherein said liposome comprises at least two bilayers of said lipid.

32. (New) The method of inhibiting the leakage according to claim 27,

wherein said liposome comprises at least two bilayers of said lipid.

33. (New) The method of inhibiting the leakage according to claim 28, wherein said liposome comprises at least two bilayers of said lipid.

34. (New) The method of inhibiting the leakage according to claim 29, wherein said liposome comprises at least two bilayers of said lipid.

35. (New) The liposome preparation according to any one of claims 16, 19 or 20 wherein said liposome comprise at least two bilayers of said lipid.

36. (New) The liposome preparation according to claim 22, wherein said liposome comprise at least two bilayers of said lipid.

37. (New) The liposome preparation according to claim 23, wherein said liposome comprise at least two bilayers of said lipid.

38. (New) The liposome preparation according to claim 24, wherein said liposome comprise at least two bilayers of said lipid.

39. (New) The liposome preparation according to claim 25, wherein said liposome comprise at least two bilayers of said lipid.